{"nctId":"NCT02695771","briefTitle":"The Bladder Instillation Comparison Study","startDateStruct":{"date":"2016-04-19","type":"ACTUAL"},"conditions":["Urinary Bladder Neoplasms"],"count":101,"armGroups":[{"label":"Mitomycin C","type":"EXPERIMENTAL","interventionNames":["Drug: Mitomycin C"]},{"label":"Gemcitabine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Gemcitabine"]},{"label":"No intervention","type":"NO_INTERVENTION","interventionNames":[]}],"interventions":[{"name":"Mitomycin C","otherNames":["Mutamycin"]},{"name":"Gemcitabine","otherNames":["Gemzar, Novaplus"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. sign an informed consent for the study\n2. be scheduled for a TURBT for suspected non-muscle invasive bladder tumor.\n\nExclusion Criteria:\n\n1. patients unable to consent for themselves\n2. individuals under 18 years old\n3. pregnant women\n4. prisoners\n5. patients with known allergy or intolerance to the mitomycin C or Gemcitabine\n6. any other sound medical, psychiatric and/or social reason as determined by the investigator.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Without Grade â‰¥ 3 Adverse Event, Graded According to NCI CTCAE Version 4.03","description":"The NCI CTCAE Version 4.03 grades adverse events as follows: grade 3 include severe but non-life-threatening consequences that result in hospitalization and/or interventions, including elective radiologic or operative interventions; grade 4 events include life-threatening consequences, such as those requiring urgent reoperation; and grade 5 events result in treatment-related death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Freedom From Bladder Stones/Dystrophic Calcification","description":"The secondary endpoint for this study will be the number of subjects who did not experience dystrophic calcification or bladder calculi measured by the number of patients with Grade 3 through Grade 5 Adverse Events that are related to study arm, graded according to NCI CTCAE Version 4.03.Version 4.03","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"25","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":29},"commonTop":["Dystrophic calcification/bladder stone","urinary retention","hematuria","Dysuria","Fever"]}}}